Cosyntropin for prophylaxis against postdural puncture headache after accidental dural puncture.

Hakim SM

Anesthesiology1 Aug 2010Cited by 32 (Europe PMC)

PMID20613476DOI10.1097/aln.0b013e3181dfd424PepBankPUB-20613476

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In parturients after accidental dural puncture, cosyntropin reduced headache incidence: 15 patients (33%) versus 31 (68.9%) with saline (P = 0.001).
In plain wordsIn parturients after accidental dural puncture, cosyntropin reduced headache incidence versus saline.
Peptide
Cosyntropin
Outcome
DecreasePostdural puncture headache incidence
Study
n = 90
Comparator
Normal saline
Outcome group
Pain · Nervous system and cognition
Studied dose
1 mg · intravenousAs given in this study (human).
Measurements
Patients with PDPH
15 patients
cosyntropin group (33%)
Patients with PDPH
31 patients
saline control group (68.9%)
Incidence of PDPH
33%
cosyntropin group
Incidence of PDPH
68.9%
saline control group
P
0.001
PDPH incidence, cosyntropin versus saline
Source sentences
Summary
Fifteen patients (33%) in the cosyntropin group suffered from PDPH, compared with 31 patients (68.9%) in the control group (P = 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Ninety parturients who suffered an ADP were studied. After delivery, patients were randomly assigned to one of two equal-sized groups. In group I (cosyntropin group), patients received cosyntropin in a dose of 1 mg intravenously. In group II (control group), patients received an equal volume of normal saline.
Report a problemFND-2061347601
02HumanRandomized controlled trialEfficacy outcome
In parturients after accidental dural puncture, cosyntropin reduced blood patch requirement: 5 patients (11.1%) versus 13 (28.9%) with saline (P = 0.035).
In plain wordsIn parturients after accidental dural puncture, cosyntropin reduced the need for a blood patch versus saline.
Peptide
Cosyntropin
Outcome
DecreaseTherapeutic epidural blood patch requirement
Study
n = 90
Comparator
Normal saline
Outcome group
Pain · Nervous system and cognition
Studied dose
1 mg · intravenousAs given in this study (human).
Measurements
Patients needing EBP
5 patients
cosyntropin group (11.1%)
Patients needing EBP
13 patients
saline control group (28.9%)
Need for EBP
11.1%
cosyntropin group
Need for EBP
28.9%
saline control group
P
0.035
EBP requirement, cosyntropin versus saline
Source sentences
Summary
Significantly fewer patients in the cosyntropin group required an EBP, compared with the control group (5 patients [11.1%] vs. 13 patients [28.9%], respectively; P = 0.035).
1 context sentence(design, population, supporting numbers)
Summary · context
Ninety parturients who suffered an ADP were studied. After delivery, patients were randomly assigned to one of two equal-sized groups. In group I (cosyntropin group), patients received cosyntropin in a dose of 1 mg intravenously. In group II (control group), patients received an equal volume of normal saline.
Report a problemFND-2061347602
03HumanRandomized controlled trialEfficacy outcome
In parturients after accidental dural puncture, headache occurrence had a hazard ratio of 0.32 with cosyntropin versus saline (95% CI = 0.16-0.55).
In plain wordsIn parturients after accidental dural puncture, cosyntropin lowered headache occurrence hazard versus saline.
Peptide
Cosyntropin
Outcome
DecreaseHazard of postdural puncture headache
Study
n = 90
Comparator
Normal saline
Outcome group
Pain · Nervous system and cognition
Studied dose
1 mg · intravenousAs given in this study (human).
Measurements
Hazard ratio
0.32
cosyntropin versus saline
95% CI
0.16 to 0.55
hazard ratio
P
< 0.0001
hazard ratio
Source sentences
Summary
The Kaplan-Meier curves for the occurrence of PDPH showed a hazard ratio of 0.32 (95% CI = 0.16-0.55, P < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
Ninety parturients who suffered an ADP were studied. After delivery, patients were randomly assigned to one of two equal-sized groups. In group I (cosyntropin group), patients received cosyntropin in a dose of 1 mg intravenously. In group II (control group), patients received an equal volume of normal saline.
Report a problemFND-2061347603
04HumanRandomized controlled trialEfficacy outcome
In parturients after accidental dural puncture, headache onset was later with cosyntropin: 27.2 [7.7] versus 17.5 [4.9] h with saline (P < 0.001).
In plain wordsIn parturients after accidental dural puncture, headache onset occurred later with cosyntropin than saline.
Peptide
Cosyntropin
Outcome
IncreaseTime to headache onset
Study
n: not reported in source
Comparator
Normal saline
Outcome group
Pain · Nervous system and cognition
Studied dose
1 mg · intravenousAs given in this study (human).
Measurements
Time from ADP to PDPH
27.2 h
cosyntropin group
Time from ADP to PDPH (bracketed value)
7.7 h
cosyntropin group
Time from ADP to PDPH
17.5 h
saline control group
Time from ADP to PDPH (bracketed value)
4.9 h
saline control group
P
< 0.001
time to PDPH, cosyntropin versus saline
Source sentences
Summary
The time from ADP to occurrence of PDPH was significantly longer in the cosyntropin group (27.2 [7.7] h) in comparison with the control group (17.5 [4.9] h; P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Ninety parturients who suffered an ADP were studied. After delivery, patients were randomly assigned to one of two equal-sized groups. In group I (cosyntropin group), patients received cosyntropin in a dose of 1 mg intravenously. In group II (control group), patients received an equal volume of normal saline.
Report a problemFND-2061347604
05HumanRandomized controlled trialEfficacy outcome
Among parturients with headache, cosyntropin and saline did not differ significantly in headache severity, duration, blood patch requirement, or repeat blood patch requirement (P > 0.05).
In plain wordsAmong parturients with headache, cosyntropin and saline did not differ significantly in headache severity, duration, or initial or repeat blood patch requirements.
Peptide
Cosyntropin
Outcome
No significant changeHeadache severity, duration, and blood patch requirements among patients with headache
Study
n: not reported in source
Comparator
Normal saline
Outcome group
Pain · Nervous system and cognition
Studied dose
1 mg · intravenousAs given in this study (human).
Measurements
P
> 0.05
severity, duration, EBP and repeat EBP among patients with PDPH
Source sentences
Summary
However, there were no statistically significant differences among patients who developed PDPH in both groups with regard to the severity or duration of PDPH or with regard to the need for EBP or for repeat EBP (P > 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Ninety parturients who suffered an ADP were studied. After delivery, patients were randomly assigned to one of two equal-sized groups. In group I (cosyntropin group), patients received cosyntropin in a dose of 1 mg intravenously. In group II (control group), patients received an equal volume of normal saline.
Report a problemFND-2061347605

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.